Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine

J Virol. 2015 Mar;89(6):3421-6. doi: 10.1128/JVI.02636-14. Epub 2014 Dec 31.

Abstract

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Viral / immunology
  • Disease Models, Animal*
  • Female
  • Humans
  • Influenza A virus / classification
  • Influenza A virus / genetics
  • Influenza A virus / immunology*
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / adverse effects
  • Influenza Vaccines / immunology
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Mice*
  • Vaccines, Attenuated / administration & dosage*
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / genetics
  • Vaccines, Attenuated / immunology

Substances

  • Antibodies, Viral
  • Influenza Vaccines
  • Vaccines, Attenuated